iBio, Inc. Statistics

Total Valuation

iBio, Inc. has a market cap or net worth of $58.91 million. The enterprise value is $8.49 million.

Market Cap	58.91M
Enterprise Value	8.49M

Important Dates

The next estimated earnings date is Thursday, May 14, 2026, before market open.

Earnings Date	May 14, 2026
Ex-Dividend Date	n/a

Share Statistics

iBio, Inc. has 36.14 million shares outstanding. The number of shares has increased by 114.82% in one year.

Current Share Class	36.14M
Shares Outstanding	36.14M
Shares Change (YoY)	+114.82%
Shares Change (QoQ)	+5.03%
Owned by Insiders (%)	2.36%
Owned by Institutions (%)	30.04%
Float	28.61M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	195.78
Forward PS	n/a
PB Ratio	0.86
P/TBV Ratio	1.12
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	28.28
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.04, with a Debt / Equity ratio of 0.04.

Current Ratio	9.04
Quick Ratio	8.93
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-145.56

Financial Efficiency

Return on equity (ROE) is -70.22% and return on invested capital (ROIC) is -41.00%.

Return on Equity (ROE)	-70.22%
Return on Assets (ROA)	-36.99%
Return on Invested Capital (ROIC)	-41.00%
Return on Capital Employed (ROCE)	-43.55%
Weighted Average Cost of Capital (WACC)	11.49%
Revenue Per Employee	$15,000
Profits Per Employee	-$1.24M
Employee Count	20
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +77.37% in the last 52 weeks. The beta is 1.36, so iBio, Inc.'s price volatility has been higher than the market average.

Beta (5Y)	1.36
52-Week Price Change	+77.37%
50-Day Moving Average	2.23
200-Day Moving Average	1.55
Relative Strength Index (RSI)	30.80
Average Volume (20 Days)	695,035

Short Selling Information

The latest short interest is 3.64 million, so 10.07% of the outstanding shares have been sold short.

Short Interest	3.64M
Short Previous Month	4.18M
Short % of Shares Out	10.07%
Short % of Float	12.73%
Short Ratio (days to cover)	3.92

Income Statement

In the last 12 months, iBio, Inc. had revenue of $300,000 and -$24.74 million in losses. Loss per share was -$1.53.

Revenue	300,000
Gross Profit	300,000
Operating Income	-25.47M
Pretax Income	-24.74M
Net Income	-24.74M
EBITDA	-24.74M
EBIT	-25.47M
Loss Per Share	-$1.53

Full Income Statement

Balance Sheet

The company has $52.70 million in cash and $2.45 million in debt, giving a net cash position of $50.25 million or $1.39 per share.

Cash & Cash Equivalents	52.70M
Total Debt	2.45M
Net Cash	50.25M
Net Cash Per Share	$1.39
Equity (Book Value)	56.56M
Book Value Per Share	1.88
Working Capital	47.47M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$18.63 million and capital expenditures -$563,000, giving a free cash flow of -$19.19 million.

Operating Cash Flow	-18.63M
Capital Expenditures	-563,000
Depreciation & Amortization	729,000
Net Borrowing	-1.13M
Free Cash Flow	-19.19M
FCF Per Share	-$0.53

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-8,491.00%
Pretax Margin	-8,245.67%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

iBio, Inc. does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-114.82%
Shareholder Yield	-114.82%
Earnings Yield	-42.12%
FCF Yield	-32.67%

Analyst Forecast

The average price target for iBio, Inc. is $4.75, which is 191.41% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$4.75
Price Target Difference	191.41%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	112.39%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on November 29, 2023. It was a reverse split with a ratio of 1:20.

Last Split Date	Nov 29, 2023
Split Type	Reverse
Split Ratio	1:20

Scores

iBio, Inc. has an Altman Z-Score of -6.14 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6.14
Piotroski F-Score	2